SCHEMBL2214589

SCHEMBL2214589

NCc1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc(-c5ccccc5)c4)cc4ccnn34)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.45
NR1H4 Q96RI1 2/20 0.44
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
LOXL2 Q9Y4K0 3/20 0.41
PLAU P00749 3/20 0.41
P2RX3 P56373 1/20 0.40
PLG P00747 3/20 0.39
KLKB1 P03952 2/20 0.39
LOX P28300 2/20 0.39
PLAT P00750 2/20 0.39
PRSS1 P07477 2/20 0.39
POLB P06746 1/20 0.39
STAT3 P40763 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211981 0.95 HDAC1 (0.45) HDAC1NR1H4KITPDGFRALOXL2
SCHEMBL2216196 0.91 PRMT1 (0.45) HDAC1NR1H4PLAUPOLBSTAT3
SCHEMBL2214607 0.91 PLAU (0.46) LOXL2PLAUPLGLOXPLAT
SCHEMBL2215099 0.91 POLB (0.47) KITPDGFRAPOLBNPC1GAA
SCHEMBL2214976 0.90 MAPT (0.47) HDAC1LOXL2PLAUPLGLOX
SCHEMBL2214363 0.90 HDAC1 (0.42) HDAC1NR1H4KITPDGFRALOXL2
SCHEMBL2214950 0.90 PTPN1 (0.46) HDAC1NR1H4KITPDGFRALOXL2
SCHEMBL2215002 0.88 JAK2 (0.45) HDAC1KITPDGFRAPOLBMAPT
SCHEMBL2215189 0.88 PLAU (0.50) LOXL2PLAUPLGLOXPLAT
SCHEMBL2215297 0.88 PTPN1 (0.45) LOXL2PLAUPLGKLKB1LOX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 HDAC1 1147/4885NR1H4 1641/4885KIT 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.